Biotechnology company Arteriocyte has received approval from the Food and Drug Administration to initiate a Phase I clinical trial with its Magellan MAR01 technology for treating compartment syndrome in extremity trauma patients.
The technology was developed in partnership with the United States Army Institute of Surgical Research, San Antonio Military Medical Center at Fort Sam Houston and Ohio State University. The project is part of Arteriocyte's Cellular Therapies for Battlefield Wounds Program.
The Magellan system is cleared for the rapid production of platelet-rich plasma from blood and bone marrow, which can be applied to a surgical site. The current clinical protocol will assess the technology's role in treating wounded military personnel who are at risk for long-term complications as a result of compartment syndrome.
More Articles on Orthopedic Devices:
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in March
Synthes & Generic Implant Company CEO Trade Lawsuits
Amedica Launches Allograft Products for Spinal Surgery
The Magellan system is cleared for the rapid production of platelet-rich plasma from blood and bone marrow, which can be applied to a surgical site. The current clinical protocol will assess the technology's role in treating wounded military personnel who are at risk for long-term complications as a result of compartment syndrome.
More Articles on Orthopedic Devices:
38 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in March
Synthes & Generic Implant Company CEO Trade Lawsuits
Amedica Launches Allograft Products for Spinal Surgery